VIVEbiotech expands viral vector capacity

Friday 1 July 2022


Spain-based VIVEbiotech SL has received regulatory approval for an upgrade of its lentiviral vector manufacturing capacity that will significantly expand its ability to produce vectors for both in vivo and ex vivo gene therapies. The company currently has 40 programmes ongoing with four dedicated to in vivo administration.